Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.1K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.1K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

651
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
651
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.2K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.2K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

1.3K
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.3K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.1K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

951
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
951

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of fat quantity and quality on the development of metabolic syndrome: findings from a 2-year cohort study.

Scientific reports·2026
Same author

Psychosomatic Susceptibility Profile (PSSP): a machine-learning-derived eight-item instrument integrating personality and coping for psychosomatic risk stratification.

Scientific reports·2026
Same author

The Effects of Fermentable Oligo-, Di-, and Monosaccharides and Polyols on Dyspeptic Symptoms: A Systematic Review and Meta-Analysis of Clinical Trials.

Health science reports·2026
Same author

Association between oxidative balance score and psychological disorders in adults.

Scientific reports·2026
Same author

Association of quantity and quality of fat intake with sleep quality: a cross-sectional study in Iran.

Osong public health and research perspectives·2026
Same author

Outcomes after treatment with proton pump inhibitors in patients with ineffective esophageal motility: a systematic review.

Gastroenterology and hepatology from bed to bench·2026

Related Experiment Video

Updated: Apr 4, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

894

Adding diclofenac to Helicobacter pylori eradication regimen.

Mohammad Hasan Emami1, Akbar Arjmandpour1, Hamed Daghaghzadeh1

  • 1Department of Internal Medicine, School of Medicine, Integrative Functional Gastroenterology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Advanced Biomedical Research
|September 1, 2015
PubMed
Summary

Diclofenac sodium may allow for a shorter, one-week treatment course for Helicobacter pylori eradication when used with standard quadruple therapy. Further research is needed to confirm the effectiveness of nonsteroidal anti-inflammatory drugs (NSAIDs) in H. pylori treatment.

Keywords:
Diclofenac NaHelicobacter pylorieradication

More Related Videos

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.7K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

442

Related Experiment Videos

Last Updated: Apr 4, 2026

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

894
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

4.7K
Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

442

Area of Science:

  • Gastroenterology and Infectious Diseases
  • Pharmacology and Therapeutics

Background:

  • Helicobacter pylori infection affects the gastric mucosa and the protective surface mucous gel layer (SMGL).
  • Diclofenac sodium is known to reduce SMGL secretion, prompting investigation into its potential role in H. pylori eradication.
  • Adjuvant therapies are crucial for improving the efficacy of standard H. pylori treatment regimens.

Purpose of the Study:

  • To evaluate the efficacy of diclofenac sodium as an adjuvant to quadruple therapy for H. pylori eradication.
  • To determine if diclofenac sodium can shorten the duration of H. pylori treatment.
  • To compare the eradication rates between standard quadruple therapy and quadruple therapy plus diclofenac sodium.

Main Methods:

  • A randomized controlled trial involving 172 patients with H. pylori infection.
  • Three treatment groups: standard quadruple therapy for 1 week (Group A), quadruple therapy plus diclofenac sodium for 1 week (Group B), and standard quadruple therapy for 2 weeks (Group C).
  • H. pylori eradication assessed via stool antigen assay 4-6 weeks post-treatment.

Main Results:

  • The H. pylori eradication rate in Group B (82.1%) was higher than in Group A (66.7%), though not statistically significant (P=0.062).
  • The eradication rate in Group B (82.1%) was comparable to Group C (82.3%) (P=0.987), suggesting a 1-week regimen with diclofenac sodium may be as effective as a 2-week standard regimen.
  • No significant difference in eradication rates was observed between the 1-week diclofenac-augmented therapy and the 2-week standard therapy.

Conclusions:

  • Diclofenac sodium may potentially shorten the duration of H. pylori eradication therapy to one week.
  • Further investigation into the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) for H. pylori eradication is warranted.
  • The findings suggest a possible role for NSAIDs in optimizing H. pylori treatment strategies.